Premium
Enzyme therapy of xeroderma pigmentosum: safety and efficacy testing of T4N5 liposome lotion containing a prokaryotic DNA repair enzyme
Author(s) -
Yarosh D.,
Klein J.,
Kibitel J.,
Alas L.,
O'Connor A.,
Cummings B.,
Grab D.,
Gerstein D.,
Gilchrest B. A.,
Ichihashi M.,
Ogoshi M.,
Ueda M.,
Fernandez V.,
Chadwick C.,
Potten C. S.,
Proby C. M.,
Young A. R.,
Hawk J. L. M.
Publication year - 1996
Publication title -
photodermatology, photoimmunology and photomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.736
H-Index - 60
eISSN - 1600-0781
pISSN - 0905-4383
DOI - 10.1111/j.1600-0781.1996.tb00188.x
Subject(s) - xeroderma pigmentosum , lotion , dna repair , enzyme , dna , erythema , dna damage , nucleotide excision repair , dermatology , medicine , chemistry , biology , microbiology and biotechnology , biochemistry , pharmacology
Xeroderma pigmentosum (XP) is a rare genetic disease in which patients are defective in DNA repair and are extremely sensitive to solar UV radiation exposure. A new treatment approach was tested in these patients, in which a prokaryotic DNA repair enzyme specific for UV‐induced DNA damage was delivered into the skin by means of topically applied liposomes to supplement the deficient activity. Acute and chronic safety testing in both mice and humans showed neither adverse reactions nor significant changes in serum chemistry or in skin histology. The skin of XP patients treated with the DNA repair liposomes had fewer cyclobutylpyrimidine dimers in DNA and showed less erythema than did control sites. The results encourage further clinical testing of this new enzyme therapy approach.